Cullinan Therapeutics Inc (NASDAQ:CGEM)’s traded shares stood at 1.03 million during the last session, with the company’s beta value hitting 0.01. At the close of trading, the stock’s price was $27.72, to imply a decrease of -5.55% or -$1.63 in intraday trading. The CGEM share’s 52-week high remains $30.19, putting it -8.91% down since that peak but still an impressive 72.44% since price per share fell to its 52-week low of $7.64. The company has a valuation of $1.19B, with an average of 704.77K shares over the past 3 months.

Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information

After registering a -5.55% downside in the last session, Cullinan Therapeutics Inc (CGEM) has traded red over the past five days. The stock hit a weekly high of 30.19, dropping -5.55% in its intraday price action. The 5-day price performance for the stock is -1.35%, and 62.77% over 30 days. With these gigs, the year-to-date price performance is 172.03%.

Cullinan Therapeutics Inc (CGEM) estimates and forecasts

Looking at statistics comparing Cullinan Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Cullinan Therapeutics Inc (CGEM) shares are 182.86% up over the last 6 months, with its year-to-date growth rate lower than industry average at 12.47% against 13.20%.

CGEM Dividends

Cullinan Therapeutics Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cullinan Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.